PepGen Inc.
PEPGPepGen Inc. in brief
PepGen Inc. is a listed company in the Biotechnology industry, based in Boston, Massachusetts, USA. It was founded in 2018. Its market value was $175 M on 26 October 2026, which makes it the 16,755th largest listed company in the world and the 3,232nd largest in the USA on this site. James G. McArthur is its chief executive. Its shares trade under the symbol PEPG (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About PepGen Inc.
PepGen Inc is a clinical stage biotechnology company focused on advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The headquarters is in Massachusetts.
PepGen Inc. timeline
- 2018
- 🏁· approximateFounded
- 2020
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2022
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 9 May 2022; shares registered for exchange trading on 3 May 2022.
Events of PepGen Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,003 (Dec 2022) · #3,874 (Jul 2023) · #3,306 (Jan 2024) · #1,369 (Mar 2026) · #3,083 (Aug 2026) · #3,244 (Oct 2026) · #3,236 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 1.2×
- Free cash flow yield
- -46.9%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -60.8%
- Liabilities / assets
- 15.2%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-94M | $-90M | — |
| Dec 2024 | — | — | $-98M | $-90M | — |
| Dec 2023 | — | — | $-85M | $-79M | — |
| Dec 2022 | — | — | $-68M | $-69M | — |
| Dec 2021 | — | — | $-27M | $-27M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-82M | $0M | $-82M | $-2.12 | — |
| Dec 2024 | $-82M | $1M | $-83M | $-2.85 | — |
| Dec 2023 | $-69M | $3M | $-72M | $-3.30 | — |
| Dec 2022 | $-59M | $4M | $-63M | $-4.42 | — |
| Dec 2021 | $-23M | $1M | $-23M | $-30.27 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-19M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportMaterial agreement · Other events
- Nov 10, 20268-KCurrent reportResults of operations · Regulation FD disclosure · Other events
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Aug 6, 20268-KCurrent reportResults of operations · Regulation FD disclosure · Other events
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Jun 22, 20268-KCurrent reportShareholder vote
- May 21, 20268-KCurrent reportRegulation FD disclosure
- May 12, 20268-KCurrent reportResults of operations
- May 12, 202610-QQuarterly report · period to Mar 2026
- Apr 28, 2026DEF 14AProxy statement
- Mar 30, 20268-KCurrent reportRegulation FD disclosure · Other events
- Mar 4, 20268-KCurrent reportRegulation FD disclosure
Official filings of PepGen Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-94 M
- Net income
- $-90 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $174 M
- Total liabilities
- $26 M
- Total equity
- $147 M
As of December-2025
Top 84 institutional investors in PepGen Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Ra Capital Management, L.P. | 20,064,545 | 0 (0.00%) | 28.97% | $49 M | Nov 16, 2026 |
| 2 | Commodore Capital LP | 4,475,000 | 0 (0.00%) | 6.46% | $11 M | Nov 16, 2026 |
| 3 | Viking Global Investors LP | 3,482,434 | 0 (0.00%) | 5.03% | $8 M | Nov 16, 2026 |
| 4 | Laurion Capital Management LP | 2,750,855 | 0 (0.00%) | 3.97% | $7 M | Oct 30, 2026 |
| 5 | Vivo Capital, LLC | 2,325,000 | 0 (0.00%) | 3.36% | $6 M | Nov 13, 2026 |
| 6 | Marshall Wace, LLP | 2,049,112 | +1,182,120 (+136.35%) | 2.96% | $5 M | Nov 13, 2026 |
| 7 | Rosalind Advisors, Inc. | 2,000,000 | +1,650,000 (+471.43%) | 2.89% | $5 M | Nov 16, 2026 |
| 8 | Vanguard Capital Management LLC | 1,977,015 | +41,095 (+2.12%) | 2.85% | $5 M | Nov 13, 2026 |
| 9 | AWM Investment Company, Inc. | 1,806,419 | +1,206,419 (+201.07%) | 2.61% | $4 M | Nov 13, 2026 |
| 10 | ADAR1 Capital Management, LLC | 1,440,874 | -1,150,211 (-44.39%) | 2.08% | $3 M | Nov 16, 2026 |
| 11 | BlackRock, Inc. | 1,346,219 | +41,957 (+3.22%) | 1.94% | $3 M | Nov 13, 2026 |
| 12 | Millennium Management LLC | 1,138,667 | -648,098 (-36.27%) | 1.64% | $3 M | Nov 16, 2026 |
| 13 | Renaissance Technologies LLC | 880,758 | -639,488 (-42.06%) | 1.27% | $2 M | Nov 12, 2026 |
| 14 | Ikarian Capital, LLC | 693,539 | +246,374 (+55.10%) | 1.00% | $2 M | Nov 16, 2026 |
| 15 | Squadron Capital Management LLC | 600,000 | New | 0.87% | $1 M | Nov 16, 2026 |
| 16 | Monimus Capital Management, LP | 587,688 | 0 (0.00%) | 0.85% | $1 M | Nov 16, 2026 |
| 17 | Susquehanna International Group, LLP | 531,055 | +455,639 (+604.17%) | 0.77% | $1 M | Nov 16, 2026 |
| 18 | Boothbay Fund Management, LLC | 499,512 | +133,371 (+36.43%) | 0.72% | $1 M | Nov 16, 2026 |
| 19 | Gsa Capital Partners LLP | 487,558 | -365,294 (-42.83%) | 0.70% | $1 M | Nov 16, 2026 |
| 20 | Geode Capital Management, LLC | 484,783 | -38,690 (-7.39%) | 0.70% | $1 M | Nov 6, 2026 |
| 21 | Citadel Advisors LLC | 399,251 | -259,130 (-39.36%) | 0.58% | $1 M | Nov 16, 2026 |
| 22 | Creek Drive Management Group LLC | 370,000 | -80,000 (-17.78%) | 0.53% | $1 M | Nov 10, 2026 |
| 23 | Jane Street Group, LLC | 296,712 | +124,300 (+72.09%) | 0.43% | $1 M | Nov 12, 2026 |
| 24 | Driehaus Capital Management LLC | 279,909 | 0 (0.00%) | 0.40% | $1 M | Nov 16, 2026 |
| 25 | Vanguard Fiduciary Trust Co | 274,892 | +13,416 (+5.13%) | 0.40% | $1 M | Nov 13, 2026 |
Show all 84: investors 26 to 84
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Connor, Clark & Lunn Investment Management Ltd. | 249,369 | +137,298 (+122.51%) | 0.36% | $1 M | Nov 10, 2026 |
| 27 | State Street Corp | 220,990 | -8,400 (-3.66%) | 0.32% | $1 M | Nov 12, 2026 |
| 28 | Artia Global Partners LP | 205,324 | 0 (0.00%) | 0.30% | $0 M | Nov 16, 2026 |
| 29 | Qube Research & Technologies Ltd | 199,551 | +100,970 (+102.42%) | 0.29% | $0 M | Nov 13, 2026 |
| 30 | Dimensional Fund Advisors LP | 181,151 | +127,038 (+234.76%) | 0.26% | $0 M | Nov 4, 2026 |
| 31 | Brendel Financial Advisors LLC | 126,321 | New | 0.18% | $0 M | Nov 9, 2026 |
| 32 | Palumbo Wealth Management LLC | 119,144 | New | 0.17% | $0 M | Nov 13, 2026 |
| 33 | Squarepoint Ops LLC | 117,215 | -411,868 (-77.85%) | 0.17% | $0 M | Nov 9, 2026 |
| 34 | Simplex Trading, LLC | 109,211 | New | 0.16% | $0 M | Nov 4, 2026 |
| 35 | Schonfeld Strategic Advisors LLC | 99,510 | New | 0.14% | $0 M | Nov 16, 2026 |
| 36 | Northern Trust Corp | 96,663 | -2,075 (-2.10%) | 0.14% | $0 M | Nov 16, 2026 |
| 37 | XTX Topco Ltd | 95,903 | -149,444 (-60.91%) | 0.14% | $0 M | Nov 16, 2026 |
| 38 | RBF Capital, LLC | 95,042 | 0 (0.00%) | 0.14% | $0 M | Nov 13, 2026 |
| 39 | Goldman Sachs Group Inc | 94,788 | -73,322 (-43.62%) | 0.14% | $0 M | Nov 16, 2026 |
| 40 | Bridgeway Capital Management, LLC | 92,276 | -1,424 (-1.52%) | 0.13% | $0 M | Nov 16, 2026 |
| 41 | Jacobs Levy Equity Management, Inc | 86,631 | New | 0.13% | $0 M | Nov 16, 2026 |
| 42 | Empowered Funds, LLC | 84,576 | New | 0.12% | $0 M | Nov 13, 2026 |
| 43 | Axq Capital, LP | 81,674 | New | 0.12% | $0 M | Nov 12, 2026 |
| 44 | Verdad Advisers, LP | 59,280 | -7,600 (-11.36%) | 0.09% | $0 M | Nov 16, 2026 |
| 45 | Quadrature Capital Ltd | 56,641 | +15,705 (+38.36%) | 0.08% | $0 M | Nov 13, 2026 |
| 46 | Jump Financial, LLC | 46,925 | New | 0.07% | $0 M | Nov 13, 2026 |
| 47 | American Century Companies Inc | 42,601 | 0 (0.00%) | 0.06% | $0 M | Nov 12, 2026 |
| 48 | Barclays PLC | 40,676 | +36,287 (+826.77%) | 0.06% | $0 M | Nov 6, 2026 |
| 49 | Rangeley Capital, LLC | 39,499 | -30,501 (-43.57%) | 0.06% | $0 M | Nov 16, 2026 |
| 50 | Citigroup Inc | 35,341 | +33,714 (+2072.16%) | 0.05% | $0 M | Nov 4, 2026 |
| 51 | Rathbones Group PLC | 32,003 | 0 (0.00%) | 0.05% | $0 M | Nov 12, 2026 |
| 52 | UBS Group AG | 29,189 | -81,484 (-73.63%) | 0.04% | $0 M | Nov 10, 2026 |
| 53 | Point72 Asset Management, L.P. | 22,726 | -16,994 (-42.78%) | 0.03% | $0 M | Nov 16, 2026 |
| 54 | HRT Financial LP | 22,677 | New | 0.03% | $0 M | Nov 13, 2026 |
| 55 | Vanguard Personalized Indexing Management, LLC | 21,166 | +3,537 (+20.06%) | 0.03% | $0 M | Nov 16, 2026 |
| 56 | Two Sigma Securities, LLC | 19,936 | New | 0.03% | $0 M | Nov 16, 2026 |
| 57 | Balyasny Asset Management L.P. | 19,008 | New | 0.03% | $0 M | Nov 16, 2026 |
| 58 | Catalyst Funds Management Pty Ltd | 18,749 | New | 0.03% | $0 M | Nov 12, 2026 |
| 59 | Bronte Capital Management Pty Ltd. | 17,776 | 0 (0.00%) | 0.03% | $0 M | Nov 12, 2026 |
| 60 | Vanguard Global Advisers, LLC | 17,723 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 61 | Two Sigma Investments, LP | 17,642 | -48,626 (-73.38%) | 0.03% | $0 M | Nov 16, 2026 |
| 62 | Hudson Bay Capital Management LP | 17,407 | New | 0.03% | $0 M | Nov 13, 2026 |
| 63 | Brevan Howard Capital Management LP | 16,921 | New | 0.02% | $0 M | Nov 16, 2026 |
| 64 | Morgan Stanley | 12,807 | -36,035 (-73.78%) | 0.02% | $0 M | Nov 13, 2026 |
| 65 | China Universal Asset Management Co., Ltd. | 12,637 | +1,629 (+14.80%) | 0.02% | $0 M | Oct 28, 2026 |
| 66 | Spark Investment Management LLC | 12,100 | New | 0.02% | $0 M | Nov 13, 2026 |
| 67 | Virtu Financial LLC | 10,695 | New | 0.02% | $0 M | Nov 17, 2026 |
| 68 | WINTON GROUP Ltd | 10,400 | New | 0.01% | $0 M | Nov 12, 2026 |
| 69 | Jpmorgan Chase & Co | 9,152 | +4,096 (+81.01%) | 0.01% | $0 M | Nov 12, 2026 |
| 70 | Royal Bank Of Canada | 8,939 | +8,878 (+14554.10%) | 0.01% | $0 M | Nov 16, 2026 |
| 71 | Zurcher Kantonalbank (Zurich Cantonalbank) | 6,111 | +1,627 (+36.28%) | 0.01% | $0 M | Nov 10, 2026 |
| 72 | Group One Trading LLC | 5,343 | -4,400 (-45.16%) | 0.01% | $0 M | Nov 10, 2026 |
| 73 | Tower Research Capital LLC (TRC) | 4,811 | -746 (-13.42%) | 0.01% | $0 M | Nov 16, 2026 |
| 74 | Mirae Asset Global Investments Co., Ltd. | 3,539 | +445 (+14.38%) | 0.01% | $0 M | Oct 29, 2026 |
| 75 | BNP Paribas Financial Markets | 2,393 | -304 (-11.27%) | 0.00% | $0 M | Nov 12, 2026 |
| 76 | FMR LLC | 1,664 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 77 | GF Fund Management Co. LTD. | 1,552 | +125 (+8.76%) | 0.00% | $0 M | Oct 26, 2026 |
| 78 | Rialto Wealth Management, LLC | 599 | +281 (+88.36%) | 0.00% | $0 M | Nov 16, 2026 |
| 79 | Bare Financial Services, Inc | 327 | 0 (0.00%) | 0.00% | $0 M | Nov 4, 2026 |
| 80 | Burk Holdings LLC | 278 | New | 0.00% | $0 M | Nov 5, 2026 |
| 81 | Nisa Investment Advisors, LLC | 195 | 0 (0.00%) | 0.00% | $0 M | Oct 20, 2026 |
| 82 | Cornerstone Financial Management LLC | 121 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 83 | Osaic Holdings, Inc. | 71 | New | 0.00% | $0 M | Nov 12, 2026 |
| 84 | Caitong International Asset Management Co., Ltd | 66 | +53 (+407.69%) | 0.00% | $0 M | Oct 29, 2026 |
Superinvestors holding PepGen Inc.
1 of the well-known investors value.today follows, from their newest Form 13F.
- Viking Global Investors · Andreas Halvorsen$8 M · Sep 30, 2026
Mutual funds holding PepGen Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.41 M | $3 M | 1.1% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 480,909 | $1 M | 0.39% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 448,519 | $1 M | 0.37% | <0.01% | −0.6% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 230,248 | $0 M | 0.19% | <0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 140,776 | $0 M | 0.11% | 0.02% | +39% | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 86,000 | $0 M | 0.07% | 0.10% | +139% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 86,249 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 69,170 | $0 M | 0.06% | <0.01% | −7.9% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 42,675 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 42,601 | $0 M | 0.03% | <0.01% | +29% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 26,673 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 19,889 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 9,517 | $0 M | <0.01% | <0.01% | +31% | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 5,789 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 1,319 | $0 M | <0.01% | <0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 237 | $0 M | <0.01% | <0.01% | +6.3% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 16 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at PepGen Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Ra Capital Management, L.P.Director, 10% owner | Buyindirect | +8.63 M | $5.000 | $43.1 M | 27.18 M | Form 4 |
| filed | Kasra KasraianChief Technical Officer | Sell10b5-1 plan | -1,233 | $1.410 | $2 K | 50,074 | Form 4 |
| filed | James G. McArthurPresident and CEO, Director | Sell10b5-1 plan | -5,144 | $6.230 | $32 K | 296,457 | Form 4 |
| filed | Paul StreckEVP, Head of R&D | Sell10b5-1 plan | -1,832 | $6.230 | $11 K | 76,273 | Form 4 |
| filed | Noel DonnellyChief Financial Officer | Sell10b5-1 plan | -2,032 | $6.230 | $13 K | 111,655 | Form 4 |
| filed | James G. McArthurPresident and CEO, Director | Sell10b5-1 plan | -131 | $6.330 | $829 | 296,326 | Form 4 |
| filed | Noel DonnellyChief Financial Officer | Sell10b5-1 plan | -52 | $6.330 | $329 | 111,603 | Form 4 |
| filed | Paul StreckEVP, Head of R&D | Sell10b5-1 plan | -47 | $6.290 | $296 | 76,226 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: PepGen Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-1.02 reverse split ; 1.018-for-1 split in the period to
Trading halts
- 2026-11-10 11:56 UTC, code T3, resumed 12:30 UTC
- 2026-03-30 20:01 UTC, code T3, resumed 20:35 UTC
- 2026-03-04 21:01 UTC, code T3, resumed 21:25 UTC
- 2025-02-24 14:30 UTC, code LUDP, resumed 14:35 UTC
Fails to deliver
- : 64 shares at $2.52
- : 56,548 shares at $2.36
- : 297 shares at $2.72
- : 1,096 shares at $2.98
- : 100 shares at $2.97
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
PepGen Inc. scorecard#
Passes 2 of the 11 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 26, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.2×Price to book 1.2× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-46.9%Free cash flow is -46.9% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-2.12 vs -2.85Diluted EPS -2.12 in fiscal 2025 against -2.85 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$90 MNet income -$90 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-67.4%-67.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities11.9×Current ratio 11.93 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year33.7%Diluted shares up 33.7% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
PepGen Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Research and development | 71−7.1%— | 76+12.3%— | 68+26.0%— | 54+185%— | 19—— | |
| General and administrative | 23+6.2%— | 21+27.8%— | 17+17.0%— | 14+75.4%— | 8.1—— | |
| Operating expenses | 94−4.2%— | 98+15.3%— | 85+24.1%— | 68+152%— | 27—— | |
| Operating income | −94—— | −98—— | −85—— | −68—— | −27—— | |
| Interest and finance income | 4.0−43.8%— | 7.1+11.6%— | 6.4+129%— | 2.8—— | — | |
| Other non-operating income (expense) | 4.0−43.9%— | 7.1+14.9%— | 6.2+114%— | 2.9—— | −0.2—— | |
| Income before tax | −90—— | −91—— | −79—— | −65—— | −27—— | |
| Income tax | 0.0—— | −0.6−945%— | 0.1−98.0%— | 3.7r3.7—— | 0—— | |
| Net income attributable to shareholders | −90—— | −90—— | −79—— | −69—— | −27—— | |
| Earnings per share, basic | -2.12—— | -2.85—— | -3.30—— | -4.42—— | -30.27—— | |
| Earnings per share, diluted | -2.12—— | -2.85—— | -3.30—— | -4.42—— | -30.27—— | |
| Shares, weighted average (basic) | 42+33.7%— | 32+32.7%— | 24+52.2%— | 16+1636%— | 0.9—— | |
| Shares, weighted average (diluted) | 42+33.7%— | 32+32.7%— | 24+52.2%— | 16+1636%— | 0.9—— | |
| Balance sheet | ||||||
| Cash and cash equivalents | 61+22.4%34.8% | 49−38.8%32.8% | 81−55.6%56.5% | 182+36.8%83.6% | 133—92.5% | |
| Short-term investments | 88+24.3%50.6% | 71+139%46.9% | 30—20.7% | 0—0.0% | — | |
| Other current assets | 2.5−29.8%1.4% | 3.6+57.2%2.4% | 2.3−47.6%1.6% | 4.3r4.3+84.5%2.0% | 2.3—1.6% | |
| Current assets | 151+22.0%86.8% | 124+9.8%82.0% | 113−39.4%78.8% | 186+32.9%85.6% | 140—97.5% | |
| Property, plant and equipment | 1.9−48.8%1.1% | 3.7−22.0%2.5% | 4.8+42.8%3.3% | 3.3+424%1.5% | 0.6—0.4% | |
| Right-of-use (leased) assets | 19−10.8%11.0% | 21−9.3%14.2% | 24−11.0%16.5% | 27—12.2% | — | |
| Total assets | 174+15.3%100% | 151+5.5%100% | 143−34.2%100% | 217+51.4%100% | 144—100% | |
| Accounts payable | 0.8−53.1%0.5% | 1.8+74.3%1.2% | 1.0−26.2%0.7% | 1.4−58.0%0.6% | 3.2—2.3% | |
| Current liabilities | 13−24.3%7.3% | 17−4.8%11.1% | 18−6.9%12.3% | 19+82.4%8.7% | 10—7.2% | |
| Lease liabilities (non-current) | 14−11.2%7.9% | 16−9.0%10.3% | 17−9.9%12.0% | 19—8.7% | — | |
| Total liabilities | 26−18.0%15.2% | 32−6.8%21.4% | 35−8.4%24.2% | 38+258%17.4% | 11—7.3% | |
| Retained earnings | −361—−208% | −271—−180% | −181—−127% | −103—−47.3% | −34—−23.5% | |
| Shareholders' equity | 147+24.3%84.8% | 119+9.4%78.6% | 108−39.6%75.8% | 180—82.6% | −32—−22.3% | |
| Total liabilities and equity | 174+15.3%100% | 151+5.5%100% | 143−34.2%100% | 217+51.4%100% | 144—100% | |
| Shares outstanding | 69+111%— | 33+36.9%— | 24+0.5%— | 24+2361%— | 1.0—— | |
| Cash-flow statement | ||||||
| Depreciation and amortization | 1.4−6.7%— | 1.5+25.0%— | 1.2+140%— | 0.5+150%— | 0.2—— | |
| Share-based compensation | 11−7.4%— | 11+62.6%— | 7.0+48.0%— | 4.8+210%— | 1.5—— | |
| Cash from operating activities | −82—— | −82—— | −69—— | −59—— | −23—— | |
| Capital expenditure | −0.3—— | −0.5—— | −2.6—— | −3.8—— | −0.5—— | |
| Cash from investing activities | −15—— | −38—— | −32—— | −3.8—— | −0.5—— | |
| Shares issued | — | 9.9—— | — | 114—— | — | |
| Cash from financing activities | 108+21.7%— | 89—— | −0.2−100%— | 112−24.0%— | 148—— | |
| Change in cash | 11—— | −31—— | −101−307%— | 49−60.8%— | 125—— | |
| Report | 10-K | 10-K | 10-K | 10-K/A | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 54−29.3%— | 14+7.8%— | 13−31.9%— | 13−48.8%— | 14*−27.0%— | 13−24.3%— | 18−26.6%— | 25+72.3%— | 19*+16.3%— | 18—— | 25—— | 15—— | 16*—— | |
| General and administrative | 24+9.1%— | 5.9+12.9%— | 6.4+15.8%— | 5.9−0.1%— | 5.9*+8.7%— | 5.2−4.0%— | 5.5+3.3%— | 5.9+17.3%— | 5.4*+19.4%— | 5.4—— | 5.4—— | 5.1—— | 4.5*—— | |
| Operating expenses | 78−20.6%— | 20+9.3%— | 19−20.9%— | 19−39.5%— | 20*−19.1%— | 19−19.5%— | 24−21.3%— | 31+58.2%— | 24*+17.0%— | 23—— | 30—— | 20—— | 21*—— | |
| Operating income | −78—— | −20—— | −19—— | −19—— | −20*—— | −19—— | −24—— | −31—— | −24*—— | −23—— | −30—— | −20—— | −21*—— | |
| Interest and finance income | 4.8+17.5%— | 1.0+58.5%— | 1.1+29.8%— | 1.3+11.4%— | 1.4*−2.8%— | 0.6−65.3%— | 0.8−60.3%— | 1.1−35.3%— | 1.5*+8.5%— | 1.8—— | 2.1—— | 1.7—— | 1.3*—— | |
| Other non-operating income (expense) | 4.8+16.6%— | 1.0+60.0%— | 1.1+35.3%— | 1.2+6.7%— | 1.4*−4.8%— | 0.6−64.9%— | 0.8−59.6%— | 1.1−37.1%— | 1.5*+7.0%— | 1.8—— | 2.1—— | 1.8—— | 1.4*—— | |
| Income before tax | −73—— | −19—— | −18—— | −18—— | −18*—— | −18—— | −23—— | −30—— | −23*—— | −21—— | −28—— | −18—— | −19*—— | |
| Income tax | 0.1—— | 0.0—— | 0.0—— | 0.0—— | 0.0*—— | 0—— | 0—— | 0—— | −0.6*—— | 0—— | 0—— | — | — | |
| Net income attributable to shareholders | −73—— | −19—— | −18—— | −18—— | −18*—— | −18—— | −23—— | −30—— | −22*—— | −21—— | −28—— | −18—— | −19*—— | |
| Earnings per share, basic | — | -0.28—— | -0.26—— | -0.26—— | — | -0.52—— | -0.70—— | -0.92—— | — | -0.66—— | -0.87—— | -0.63—— | — | |
| Earnings per share, diluted | — | -0.28—— | -0.26—— | -0.26—— | — | -0.52—— | -0.70—— | -0.92—— | — | -0.66—— | -0.87—— | -0.63—— | — | |
| Shares, weighted average (basic) | 69+102%— | 69+102%— | 69+111%— | 69+111%— | — | 34+5.5%— | 33+0.9%— | 33+14.0%— | — | 33—— | 32—— | 29—— | — | |
| Shares, weighted average (diluted) | 69+102%— | 69+102%— | 69+111%— | 69+111%— | — | 34+5.5%— | 33+0.9%— | 33+14.0%— | — | 33—— | 32—— | 29—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 22—17.2% | 22−84.6%17.2% | 23−35.1%16.1% | 42−3.4%27.0% | 61+22.4%34.8% | 143+238%75.1% | 35−46.9%34.3% | 44−67.4%34.3% | 49−38.8%32.8% | 42—24.8% | 66—34.2% | 134—64.7% | 81—56.5% | |
| Short-term investments | 83—64.8% | 83+297%64.8% | 94+139%66.8% | 90+66.5%57.7% | 88+24.3%50.6% | 21−78.4%11.0% | 40−58.4%38.7% | 54+30.9%42.5% | 71+139%46.9% | 97—56.7% | 95—49.2% | 41—20.0% | 30—20.7% | |
| Other current assets | 2.8—2.2% | 2.8+8.7%2.2% | 3.1+9.1%2.2% | 2.0−39.7%1.3% | 2.5−29.8%1.4% | 2.5−27.6%1.3% | 2.8−18.4%2.8% | 3.3+36.3%2.6% | 3.6+57.2%2.4% | 3.5—2.1% | 3.5—1.8% | 2.4—1.2% | 2.3—1.6% | |
| Current assets | 108—84.2% | 108−35.3%84.2% | 120+55.3%85.1% | 134+32.9%85.9% | 151+22.0%86.8% | 166+16.7%87.5% | 77−53.0%75.8% | 101−43.1%79.3% | 124+9.8%82.0% | 142—83.6% | 165—85.2% | 178—85.8% | 113—78.8% | |
| Property, plant and equipment | 1.1—0.9% | 1.1−50.4%0.9% | 1.3−46.1%0.9% | 1.6−55.4%1.0% | 1.9−48.8%1.1% | 2.2−43.1%1.2% | 2.5−41.2%2.4% | 3.5−21.0%2.8% | 3.7−22.0%2.5% | 3.9—2.3% | 4.2—2.2% | 4.4—2.1% | 4.8—3.3% | |
| Right-of-use (leased) assets | 17—13.5% | 17−12.3%13.5% | 18−11.7%12.7% | 19−11.2%11.9% | 19−10.8%11.0% | 20−10.4%10.4% | 20−10.0%19.8% | 21−9.6%16.4% | 21−9.3%14.2% | 22—12.9% | 23—11.6% | 23—11.2% | 24—16.5% | |
| Total assets | 128—100% | 128−32.8%100% | 141+38.3%100% | 156+22.7%100% | 174+15.3%100% | 190+11.6%100% | 102−47.2%100% | 127−38.5%100% | 151+5.5%100% | 170—100% | 194—100% | 207—100% | 143—100% | |
| Accounts payable | 1.9—1.5% | 1.9+149%1.5% | 1.1+27.9%0.8% | 0.6−77.0%0.4% | 0.8−53.1%0.5% | 0.8−87.1%0.4% | 0.9−88.9%0.8% | 2.7+82.4%2.1% | 1.8+74.3%1.2% | 5.9—3.5% | 7.7—4.0% | 1.5—0.7% | 1.0—0.7% | |
| Current liabilities | 12—9.7% | 12−2.2%9.7% | 9.0−45.0%6.4% | 9.0−56.1%5.7% | 13−24.3%7.3% | 13−24.8%6.7% | 16−26.0%16.0% | 20+81.5%16.0% | 17−4.8%11.1% | 17—9.9% | 22—11.4% | 11—5.4% | 18—12.3% | |
| Lease liabilities (non-current) | 12—9.7% | 12−13.5%9.7% | 13−12.7%9.1% | 13−11.9%8.5% | 14−11.2%7.9% | 14−10.6%7.5% | 15−10.0%14.4% | 15−9.5%11.9% | 16−9.0%10.3% | 16—9.4% | 16—8.5% | 17—8.1% | 17—12.0% | |
| Total liabilities | 25—19.3% | 25−8.2%19.3% | 22−29.7%15.5% | 22−37.3%14.3% | 26−18.0%15.2% | 27−17.9%14.2% | 31−19.2%30.4% | 36+27.1%27.9% | 32−6.8%21.4% | 33—19.3% | 38—19.9% | 28—13.5% | 35—24.2% | |
| Retained earnings | −416—−326% | −416—−326% | −397—−281% | −379—−242% | −361—−208% | −343—−180% | −325—−318% | −302—−237% | −271—−180% | −249—−146% | −228—−118% | −200—−96.4% | −181—−127% | |
| Shareholders' equity | 103—80.7% | 103−36.8%80.7% | 120+68.0%84.5% | 134+45.9%85.7% | 147+24.3%84.8% | 163+18.7%85.8% | 71−54.1%69.6% | 92−48.7%72.1% | 119+9.4%78.6% | 137—80.7% | 155—80.1% | 179—86.5% | 108—75.8% | |
| Total liabilities and equity | 128—100% | 128−32.8%100% | 141+38.3%100% | 156+22.7%100% | 174+15.3%100% | 190+11.6%100% | 102−47.2%100% | 127−38.5%100% | 151+5.5%100% | 170—100% | 194—100% | 207—100% | 143—100% | |
| Shares outstanding | — | — | — | — | 69+111%— | — | — | — | 33+36.9%— | — | — | — | 24—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 1.1−21.4%— | 0.2−33.3%— | 0.30.0%— | 0.3−25.0%— | 0.3*−25.0%— | 0.3−25.0%— | 0.3−25.0%— | 0.40.0%— | 0.4*0.0%— | 0.4—— | 0.4—— | 0.4—— | 0.4*—— | |
| Share-based compensation | 12+0.4%— | 3.0+24.7%— | 3.3+40.2%— | 2.9−16.8%— | 2.4*−27.2%— | 2.4−26.3%— | 2.4−17.4%— | 3.4+69.7%— | 3.3*+74.1%— | 3.2—— | 2.9—— | 2.0—— | 1.9*—— | |
| Cash from operating activities | −63—— | −13*—— | −16*—— | −18—— | −16*—— | −19*—— | −24*—— | −23—— | −19*—— | −24*—— | −16*—— | −23—— | −19*—— | |
| Capital expenditure | — | 0*—— | −0.0*—— | 0—— | — | −0.1*—— | −0.0*—— | −0.1—— | −0.2*—— | −0.2*—— | −0.0*—— | −0.1—— | −0.2*—— | |
| Cash from investing activities | −59−176%— | 12*−34.1%— | −3.5*−124%— | −1.5−109%— | −66*−350%— | 19*—— | 15*—— | 17—— | 27*—— | −0.1*—— | −53*—— | −11—— | −30*—— | |
| Shares issued | — | 0*—— | 0*—— | 1.5—— | — | 0*—— | 0*—— | 0−100%— | 0*—— | 0*—— | 0*—— | 9.9—— | — | |
| Cash from financing activities | 1.2−98.9%— | −0.1*−100%— | −0.1*−166%— | 1.5—— | −0.2*−234%— | 108*+32943%— | 0.1*−92.6%— | 0−100%— | 0.1*+392%— | 0.3*—— | 1.3*—— | 87—— | 0.0*—— | |
| Change in cash | −121−220%— | −0.8*−101%— | −19*—— | −18—— | −82*−1253%— | 108*—— | −8.6*—— | −5.8−111%— | 7.1*—— | −24*—— | −68*—— | 53—— | −49*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at PepGen Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 4 · Material agreement 2 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at PepGen Inc.#
3 labor condition applications certified in fiscal 2024 for 3 positions, at a median wage of $177 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Director, Regulatory StrategistRegulatory Affairs Managers | 1 | $230 K |
| Principal Scientist, Associate DirectorBiochemists and Biophysicists | 1 | $177 K |
| Sr. Specialist, Quality AssuranceRegulatory Affairs Specialists | 1 | $110 K |
Where: Boston, MA 3
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2024 | 3 | 3 | $177 K | 3 |
| FY2023 | 1 | 1 | $255 K | 1 |
| FY2022 | 2 | 2 | $155 K | 2 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as PepGen Inc.
How PepGen Inc. compares in Biotechnology
- Market cap$175 M · higher than 42% of 726
- Price / book1.2× · lower than 76% of 534
- FCF yield-46.9% · higher than 25% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| PepGen Inc.🇺🇸 | $175 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 26, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at PepGen Inc.? Verify and update this profile — free
Show PepGen Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.